Regeneron falls after appeals court ruling in Eylea case (update)
Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 3% after the company's loss against Amgen (AMGN) and others in a patent case ...
Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...
pharmaphorum2d
Regeneron set for August FDA decision on BCMA bispecific
Regeneron’s bid to join the market for BCMA-targeted bispecific antibodies for multiple myeloma is nearing a conclusion, with the FDA starting a priority review of its linvoseltamab drug candidate.
Supreme Court Should Resolve False Claims Act Causation Question
Attorney Stuart Silverman says the First Circuit’s widening the divide on the False Claims Act’s causation standard adds to ...
Regeneron finalists from Long Island go to Washington for a shot at up to $250,000 in prize money
Wen is among the 40 finalists heading to Washington, D.C., Thursday to present their projects to panels of experts. The ...
Cancer Therapy Advisor3d
Linvoseltamab Under Review for Relapsed/Refractory Multiple Myeloma
The FDA has accepted the resubmitted BLA for linvoseltamab for patients with relapsed/refractory multiple myeloma.
TMCnet2d
Genmab, NHS England, Pistoia Alliance and Regeneron Win Bio-IT World Innovative Practices Awards
BOSTON, March 21, 2025 /PRNewswire/ -- Bio-IT World has named Genmab, NHS (National Health Service) England, Pistoia Alliance ...